Brazilian Coronary ARtery Disease (BARD)

April 30, 2025 updated by: University of Sao Paulo General Hospital

The Brazilian Coronary Disease Cohort

Although coronary artery disease may have a stable chronic clinical course, it is known that this reality does not apply to atherosclerotic plaques, they can grow, complicate, stabilize and again start new cycles of growth/destabilization/stabilization or quiescence in the presence or absence of symptoms. While in obstructive coronary lesions there are well-founded guidelines based on multiple clinical studies, in relation to investigation and treatment; on the other hand, in non-obstructive lesions, there are no such guidelines. There are gaps in the knowledge about the prognostic implications of minor injuries and the occurrence of events. This study seeks precisely to fill these knowledge gaps. Of particular relevance are the large number of patients (approximately 10,000 patients) and the long clinical follow-up, that is, in eight years.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Introduction:

For decades, patients with obstructive coronary disease, specifically with lesions above 70%, have been the subject of numerous randomized studies and meta-analyses concerning the influence of drug treatments, revascularization (surgical or percutaneous), and lifestyle on their prognosis. In this scenario, the investigators already have a reasonable knowledge of the behaviors most appropriate for both avoiding events and alleviating symptoms. However, one particular subgroup consists of patients whose lesions are non-obstructive. In most cases, these are considered lesions of ≤70%. Many individuals presented obstructive lesions that were deemed appropriate for angioplasty within this classification. For example, in the study Defer of 325 patients with indications of ischemia, 44.3% presented FFR (fractional flow reserve) ≤0.75, which suggested significant obstruction, and were submitted to ATC. Thus, the investigators consider the threshold ≤70% inappropriate since it includes many patients with ischemia when assessed by FFR. Therefore, this study has decided to investigate patients with lesions of ≤50% on the supposition that they do not have obstructive lesions. In addition, although coronary disease may follow a stable clinical course, this is not the case with atherosclerotic plaques. These can grow, become complex, stabilize and reinitiate new cycles of growth/destabilization/stabilization or inactivity, in either the presence or absence of evident symptoms. Though aware of this dynamic, studies were performed to "photograph" at a given time subclinical atherosclerotic load and correlate it to the incidence of the events. The indicators most used for evaluating atherosclerotic load have been the presence of extra-cardiac atherosclerosis (carotid ultrasound) and calcification of the coronary arteries. Furthermore, the calcium score has been used for the same purpose in the Brazilian population: but only as a prognostic indicator among carriers of family hypercholesterolemia. However, there are considerable doubts concerning therapeutic interventions in asymptomatic patients with no critical stenosis. Given this gap, chiefly among the Brazilian population, and being an institution with one of the highest volumes of medical care and screening for coronary disease globally, the investigators have all the necessary conditions to put this important public health problem into perspective.

Objectives:

To evaluate clinical evolution, in eight years, of patients with no coronary lesions or lesions <50%, invasive coronary angiography (ICA) exams or coronary angiotomography is performed for the diagnosis of coronary disease.

Population:

Patients were referred to Instituto do Coração (InCor HCFMUSP) for ICA or angiotomography for diagnosis of coronary heart disease from January 1, 2011, to December 31, 2017. Exclusion criteria: age under 18 years or over 80 years at the time of examination, previous history of an acute coronary syndrome (infarction and unstable angina), revascularization interventions (surgical or percutaneous), valvular heart disease, cardiomyopathies, or diseases with a poor prognosis (expected survival of fewer than eight years). The cohort will be composed of 3 groups: the control group (without coronary lesions), lesion group <30%, and lesion group >30% to <50%. Study type: an observational, retrospective, with data from the database of InCor, (Heart Institute - InCor, University of São Paulo). Outcomes: primary composite (general death, acute myocardial infarction, cerebrovascular accident, need for revascularization); secondary outcomes: the isolated components of the primary outcome at eight years.

Data to be collected:

Age (on the date of examination), gender, presence of risk factors - arterial hypertension (BP >130/85; or use of antihypertensive medication), diabetes mellitus (fasting glucose ≥126 mg/dL, casual >140 mg/dL or GTT >200 mg/dL, or use of oral or injectable hypoglycemic agents), dyslipidemia (LDL >130 mg/dL, triglycerides >150 mg), lipid levels (total cholesterol, HDL-C, LDL-C, and triglycerides); tobacco user (never, ex-tobacco user, active), obesity, exercise, family history, creatinine, chronic kidney disease (glomerular filtration <60 mL/1.73m²/min).

Medications in use: ACE inhibitors/ARB; statins; AAS; Beta-blockers and calcium channel antagonists, and diuretics.

Clinical status: angina and/or dyspnea. Left ventricular systolic function: normal left ventricular ejection fraction (LVEF) (50%), mild decrease (≥45% to <50%); moderate (>35% to 45%) and severe (<35%).

Cardiovascular history: cerebrovascular accident or peripheral arterial disease.

Atherosclerotic load: a) Higher percentage of obstruction of the lumen by comparing the diameter in the lesion region with its proximal neighborhood: absent (0%), very mild (1-30%), and mild (30-49%), for eligibility of each group studied; b) Total lesion score: zero for absence, 1 for minor injuries(<30%), and 2 for minor injuries(30-50%). Multiplied by their frequency and totaled at the end; c) The atherosclerotic load will be weighted using the Syntax scores for its location, though the lesions are less than 50%. Left coronary trunk = 5; proximal AD = 3.5; medial AD = 1.5; distal AD = 1; diagonal = 1; proximal circumflex = 1.5; distal = 1; marginal = 1; proximal or distal right coronary artery = 1 and posterior descending artery = 1; coronary calcium score (CAC).

Population:

Patients underwent invasive coronary angiography (ICA) or coronary computed tomography angiography at InCor from January 2011 to December 2014. To allow 5-year follow-up (FU) of all cases. The investigators estimate the inclusion of approximately 5,000 patients, with a minimum of 1,500 in the control group.

Deadlines for execution and analysis:

The investigators anticipate including an average of 40 patients per day and completion at the end of 2 years. The rate of scheduled events should not exceed 0.5% to 1% per year, so the investigators plan interim analyses at two years FU when the investigators would have at least 600 events for analysis.

Clinical, laboratory, and image data:

Electronic Patient Care System SI3 of InCor will be used to screen and follow the patients. Patients who have not been followed regularly at ambulatory clinics of InCor will be contacted by phone or e-mail to ascertain their evolution. In cases of death, family members or attending physicians will be contacted. Death certificates will be analyzed to adjudicate death´s causes. Eventually, the Foundation for the State System of Data Analysis (SEADE) database from Estado de São Paulo will be used.

Study Type

Observational

Enrollment (Actual)

4004

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
      • São Paulo, Brazil, 05403-000
        • Instituto do Coração InCor, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients referred to Instituto do Coração (InCor HC, FM-USP) for invasive coronary angiography or angiotomography, for diagnosis of coronary heart disease from January 1, 2011 to December 31, 2017.

Description

Inclusion Criteria:

• Patients referred to Instituto do Coração (InCor HC, FM-USP) for invasive coronary angiography or angiotomography.

Exclusion Criteria:

  • Age under 18 years or over 80 years at the time of examination;
  • Previous history of acute coronary syndrome (infarction and unstable angina);
  • Revascularization interventions (surgical or percutaneous);
  • Valvular heart disease;
  • Cardiomyopathies;
  • Diseases with a poor prognosis (expected survival of less than 8 years).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control group (without coronary lesions)
Cohort control group. No interventions.
Other: No intervention
No intervention. It is an observational study
Coronary Lesion < 30%
Participants with coronary lesion under 30%. No interventions.
Other: No intervention
No intervention. It is an observational study
Coronary Lesion > 30% and < 50%
Participants with coronary lesions greater than 30% and under 50%. No interventions.
Other: No intervention
No intervention. It is an observational study

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with Composite Outcome
Time Frame: 8 years
Participants presenting the following outcomes: death of any cause, acute myocardial infarction, stroke, and need for revascularization.
8 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with acute myocardial infarction
Time Frame: 8 years
According to classical definition: clinical, electrocardiography and enzymes
8 years
Number of participants with stroke
Time Frame: 8 years
Loss of consciousness and hemiplegia
8 years
Number of participants needing revascularization
Time Frame: 8 years
Coronaries bypass surgery or angioplasty
8 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Sao Paulo General Hospital

Investigators

  • Principal Investigator: Protasio Luz, PhD, Instituto do Coração InCor, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2022

Primary Completion (Actual)

May 1, 2024

Study Completion (Actual)

November 1, 2024

Study Registration Dates

First Submitted

May 17, 2022

First Submitted That Met QC Criteria

May 24, 2022

First Posted (Actual)

May 26, 2022

Study Record Updates

Last Update Posted (Actual)

May 4, 2025

Last Update Submitted That Met QC Criteria

April 30, 2025

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BARD Study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe